Key Highlights

  • Enveda Therapeutics closed a USD 311 million Series E funding round.
  • Catalio Capital Management led the round, with Iconiq among other participants.
  • The round values the company at USD 2 billion.
  • CEO Viswa Colluru is advancing candidates for severe skin conditions and for maintaining weight loss after stopping GLP-1 drugs.

A Major Series E at a Doubled Valuation

Enveda Therapeutics, an AI-driven drug discovery biotech led by Chief Executive Officer Viswa Colluru, closed a USD 311 million Series E funding round led by Catalio Capital Management, with Iconiq among the other participating investors, valuing the company at USD 2 billion. A raise of this size at this valuation level signals strong continued investor confidence in the company's AI-driven approach to drug discovery, even amid a broader funding environment that has grown more selective for early and growth-stage biotech companies.

A Pipeline Spanning Skin Conditions and Weight Maintenance

Enveda's pipeline includes at least two clinical-stage candidates, one targeting severe skin conditions and another aimed at helping patients maintain weight loss after discontinuing GLP-1 drugs, a category addressing an emerging clinical need as the broader GLP-1 market matures and more patients eventually stop taking these medications. A candidate specifically targeting post-GLP-1 weight maintenance addresses a distinct commercial opportunity from the GLP-1 drugs themselves, potentially capturing value from patients transitioning off primary GLP-1 therapy.

AI's Role in the Company's Discovery Approach

Enveda's positioning as an AI-driven drug discovery biotech reflects a broader trend of investors continuing to back companies that apply artificial intelligence and machine-learning techniques to identify and develop novel drug candidates more efficiently than traditional discovery approaches. The scale of this Series E round suggests investors remain willing to commit substantial capital to companies that can demonstrate a credible, differentiated AI-driven approach paired with clinical-stage pipeline progress.

Where Things Stand

Enveda Therapeutics' USD 311 million Series E round, valuing the AI-driven drug discovery biotech at USD 2 billion, reflects sustained investor confidence in the company's approach even as it advances candidates addressing both severe skin conditions and the emerging post-GLP-1 weight maintenance opportunity. Continued clinical progress on these candidates will likely be the key driver of the company's next value inflection point.